LABU241018C143000
- 0.27
- +0.04+17.39%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Natera Analyst Ratings
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
Looking Into AbbVie's Recent Short Interest
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and More
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
A Look Into Incyte Inc's Price Over Earnings
Peering Into United Therapeutics's Recent Short Interest
Incyte Analyst Ratings
CareDx Stock Climbs 7% Amid Reports Natera Not Pursuing Litigation
Alnylam Pharmaceuticals Analyst Ratings
AbbVie Snaps Six Days of Losses, Trades in the Green
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Insmed Analyst Ratings
(EXAS) - Analyzing Exact Sciences's Short Interest